Third Quarter Earnings Call - AMPHASTAR PHARMACEUTICALS INC

Financial Performance:

• Q3 2026 revenue reached a record $207.6 million, representing an 8% year-over-year and 13% sequential increase.
• Gross margin decreased to 48% from 51% YoY, driven by lower net pricing on Baximi, Glucagon, and epinephrine, alongside $2–3 million in incremental manufacturing costs at the IMS facility.
• Net income rose to $37.8 million ($0.87/share) from $17.4 million ($0.37/share); Adjusted net income increased to $49.3 million ($1.14/share) from $44.7 million ($0.93/share).
• Operating cash flow was approximately $43.3 million for the quarter.
• G&A expenses decreased 57% to $16.8 million due to the absence of a legal settlement in the prior year; R&D expenses decreased 10% to $20.1 million, excluding one-time licensing payments from the prior year.
• The Board authorized an additional $50 million share buyback program.

Guidance and Future Outlook:

• Q4 2026 sales are expected to grow in the high single-digit range, incorporating a modest slowdown in IMS sales due to remediation priorities.
• Full-year 2026 outlook is being updated based on current performance and remediation timelines; no specific 2027 guidance provided yet, though strong growth is anticipated from Baximi, Primatine Mist, and Ipratropium Bromide annualizing.
• Insulin Aspart biosimilar launch remains on track for 2027, subject to FDA approval.
• IMS facility remediation is expected to allow a return to full capacity by mid-2027.
• AMP 018 (GLP-1 generic) launch is expected in late 2027; AMP 104 (new Primatine) filing target is set for end of 2028.

Business Segments and Product Lines:

• Vaxini (Vaccine): Sales of $58.8 million (+10% YoY), driven by volume growth of 7.4 million units, partially offset by lower ASPs due to rebate and 340B discount headwinds.
• Primatine Mist: Record sales of $31.5 million (+9% YoY), fueled by a Q2 price increase and 2.5% increase in in-store unit sales.
• New Launches: Ipratropium bromide generated $6.6 million in Q3; Teriparatide contributed $6.4 million; both expected to sustain growth in 2027.
• Lidocaine: Sales surged 29% to $16.6 million due to supplier shortages and increased demand.
• Challenged Products: Epinephrine sales declined 19% to $15.3 million and Glucagon sales fell 37% to $8.6 million due to IMS remediation delays and competition, respectively.
• API: ANP subsidiary contributed $6.2 million in API sales.

Market and Competitive Landscape:

• Duplicate 340B discounting ("double dipping") remains a pricing headwind, though impact has significantly reduced compared to previous quarters; management estimates ~80% resolution, with a remaining $2.2 million pricing drag in Q3.
• Market share growth continues for Vaxini and Ipratropium bromide, the latter currently being the only generic in its market.
• Insulin biosimilar market is crowded with 3–4 competitive generics, but the company believes the large market size allows for viable entry.
• GLP-1 generic competition is expected to limit the market opportunity for AMP 018.
• EPA regulatory changes regarding HFA propellants necessitated the development of the AMP 104 Primatine variant to maintain compliance and IP protection.

Risks and Challenges:

• IMS Facility Remediation: Ongoing FDA warning letter compliance efforts are causing production delays, higher manufacturing costs ($2–3M incremental expense in Q3), and supply constraints for specific products.
• Pricing Pressures: Lower average selling prices on key franchise products (Baximi, Glucagon) continue to compress margins.
• Supply Chain Constraints: Tight manufacturing capacity and high backorders (up to $12.5 million) at the IMS facility limit the ability to capitalize on demand spikes for other products like Lidocaine.
• Product Concentration: Declines in legacy products (Glucagon, Epinephrine) highlight reliance on new launches and specific commercial strengths to offset volume losses.

Management Commentary and Tone:

• Management maintained a confident and disciplined tone, emphasizing the strength of the commercial platform and the success of recent launches.
• Repeatedly highlighted the "operational rather than demand-related" nature of recent challenges at the IMS facility.
• Expressed satisfaction with progress on 340B remediation, noting the pricing headwind is "significantly smaller" than in prior quarters.
• Reinforced the strategy of vertical integration and U.S. manufacturing as competitive advantages for future growth.

Analyst Questions and Answers:

• 340B Discounting: Management confirmed they are approaching 80% resolution but do not expect full restoration to historical pricing levels, citing structural changes in the market.
• IMS Facility Impact: Confirmed $2–3 million incremental expense in Q3 with likely higher costs in the next 2–3 quarters; FDA involvement is ongoing via routine updates on a comprehensive remediation plan.
• Product Specifics:
  • Lidocaine: Demand expected to hold in 2027, but delivery limited by IMS capacity constraints.
  • Ipratropium: Sales expected to continue growing beyond the $25M annualized run-rate; no new generic entrants currently anticipated.
  • Insulin Biosimilar: Launch timing is not specific to Q1 2027; margin profile acknowledged as impacted by competitive generics but viewed as a large opportunity.
  • AMP 104: Development driven by EPA/FDA regulations on HFA propellants; patent filing ongoing to extend IP.
• Development Delays: Minor delays in AMP 005/017 filings attributed to normal development processes rather than data issues or FDA feedback.

Other Key Points:

• The company operates a vertically integrated model with U.S.-based manufacturing capabilities.
• A backlog of approximately $12.5 million at the IMS facility exists due to increased quality controls; reducing this backlog is a priority for Q4.
• AMP 101 (intranasal epinephrine) advanced Phase I; AMP 109 (oncology) and AMP 110 (corticotropin) are in non-clinical/pre-clinical stages.
• The Q3 results were described as a "record commercial performance" despite operational headwinds.